Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s stock price gapped up prior to trading on Monday . The stock had previously closed at $29.38, but opened at $31.34. Metsera shares last traded at $28.95, with a volume of 265,955 shares traded.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. Guggenheim increased their price target on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Evercore ISI started coverage on Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating for the company. Cantor Fitzgerald assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating for the company. Finally, Bank of America assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target on the stock.
Get Our Latest Report on Metsera
Metsera Price Performance
The business has a 50 day moving average of $25.09.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of Metsera in the first quarter valued at $76,000. New York State Common Retirement Fund bought a new position in Metsera during the 1st quarter valued at about $131,000. Corebridge Financial Inc. purchased a new stake in Metsera in the 1st quarter worth about $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Metsera in the 1st quarter worth about $248,000. Finally, MetLife Investment Management LLC bought a new stake in Metsera in the first quarter worth about $254,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
